IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University

Reuters11-07

IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University

IN8bio Inc. has announced the expansion of its Phase 1 INB-100 clinical trial to The James Comprehensive Cancer Center at The Ohio State University, aiming to accelerate patient enrollment for this study of donor-derived, allogeneic gamma-delta (γδ) T cell therapy in patients with leukemias undergoing haploidentical stem cell transplantation. Additionally, the company presented new preclinical data on INB-619, a CD19-targeting γδ T cell engager, at the 2025 American College of Rheumatology $(ACR)$ Convergence Meeting. The preclinical results demonstrated that INB-619 achieved complete elimination of B cells in systemic lupus erythematosus $(SLE)$ donor models, with efficacy comparable to currently FDA-approved CD19 and CD20 engagers. Updated clinical data for INB-200/400 in newly diagnosed glioblastoma are planned to be presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581201001?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581201001","market":"fut","top_or_hot":-1,"title":"IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IN8bio Inc. has announced the expansion of its Phase 1 INB-100 clinical trial to The James Comprehensive Cancer Center at The Ohio State University, aiming to accelerate patient enrollment for this study of donor-derived, allogeneic gamma-delta (γδ) T cell therapy in patients with leukemias undergoing haploidentical stem cell transplantation. Additionally, the company presented new preclinical data on INB-619, a CD19-targeting γδ T cell engager, at the 2025 American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Convergence Meeting. The preclinical results demonstrated that INB-619 achieved complete elimination of B cells in systemic lupus erythematosus <a href=\"https://laohu8.com/S/SLE\">$(SLE)$</a> donor models, with efficacy comparable to currently FDA-approved CD19 and CD20 engagers. Updated clinical data for INB-200/400 in newly diagnosed glioblastoma are planned to be presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IN8bio Inc. has announced the expansion of its Phase 1 INB-100 clinical trial to The James Comprehensive Cancer Center at The Ohio State University, aiming to accelerate patient enrollment for this study of donor-derived, allogeneic gamma-delta (γδ) T cell therapy in patients with leukemias undergoing haploidentical stem cell transplantation. Additionally, the company presented new preclinical data on INB-619, a CD19-targeting γδ T cell engager, at the 2025 American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Convergence Meeting. The preclinical results demonstrated that INB-619 achieved complete elimination of B cells in systemic lupus erythematosus <a href=\"https://laohu8.com/S/SLE\">$(SLE)$</a> donor models, with efficacy comparable to currently FDA-approved CD19 and CD20 engagers. Updated clinical data for INB-200/400 in newly diagnosed glioblastoma are planned to be presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL8bK3hQ:1","article_id":"2581201001","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581201001","pubTimestamp":1762463676,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IN8bio Inc. has announced the expansion of its Phase 1 INB-100 clinical trial to The James Comprehensive Cancer Center at The Ohio State University, aiming to accelerate patient enrollment for this study of donor-derived, allogeneic gamma-delta (γδ) T cell therapy in patients with leukemias undergoing haploidentical stem cell transplantation. Additionally, the company presented new preclinical data on INB-619, a CD19-targeting γδ T cell engager, at the 2025 American College of Rheumatology  Convergence Meeting. The preclinical results demonstrated that INB-619 achieved complete elimination of B cells in systemic lupus erythematosus  donor models, with efficacy comparable to currently FDA-approved CD19 and CD20 engagers. Updated clinical data for INB-200/400 in newly diagnosed glioblastoma are planned to be presented at the 2025 Society for Neuro-Oncology  Annual Meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","INAB":"IN8bio, Inc."},"translate_title":"IN8BIO将INB-100 γ-δ T细胞疗法1期试验扩展至俄亥俄州立大学","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INAB":0.9},"content_text":"IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University\n    \n\n        IN8bio Inc. has announced the expansion of its Phase 1 INB-100 clinical trial to The James Comprehensive Cancer Center at The Ohio State University, aiming to accelerate patient enrollment for this study of donor-derived, allogeneic gamma-delta (γδ) T cell therapy in patients with leukemias undergoing haploidentical stem cell transplantation. Additionally, the company presented new preclinical data on INB-619, a CD19-targeting γδ T cell engager, at the 2025 American College of Rheumatology $(ACR)$ Convergence Meeting. The preclinical results demonstrated that INB-619 achieved complete elimination of B cells in systemic lupus erythematosus $(SLE)$ donor models, with efficacy comparable to currently FDA-approved CD19 and CD20 engagers. Updated clinical data for INB-200/400 in newly diagnosed glioblastoma are planned to be presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581201001","isCrawlerRequest":true}